114 related articles for article (PubMed ID: 20116128)
1. Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
Keith RL; Karoor V; Mozer AB; Hudish TM; Le M; Miller YE
Lung Cancer; 2010 Oct; 70(1):37-42. PubMed ID: 20116128
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice.
Keith RL; Miller YE; Hudish TM; Girod CE; Sotto-Santiago S; Franklin WA; Nemenoff RA; March TH; Nana-Sinkam SP; Geraci MW
Cancer Res; 2004 Aug; 64(16):5897-904. PubMed ID: 15313935
[TBL] [Abstract][Full Text] [Related]
3. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma.
Nemenoff R; Meyer AM; Hudish TM; Mozer AB; Snee A; Narumiya S; Stearman RS; Winn RA; Weiser-Evans M; Geraci MW; Keith RL
Cancer Prev Res (Phila); 2008 Oct; 1(5):349-56. PubMed ID: 19138979
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
5. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer.
Keith RL; Miller YE; Hoshikawa Y; Moore MD; Gesell TL; Gao B; Malkinson AM; Golpon HA; Nemenoff RA; Geraci MW
Cancer Res; 2002 Feb; 62(3):734-40. PubMed ID: 11830527
[TBL] [Abstract][Full Text] [Related]
6. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Zerbe LK; Dwyer-Nield LD; Fritz JM; Redente EF; Shroyer RJ; Conklin E; Kane S; Tucker C; Eckhardt SG; Gustafson DL; Iwata KK; Malkinson AM
Cancer Chemother Pharmacol; 2008 Sep; 62(4):605-20. PubMed ID: 18030469
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
8. PPARĪ³ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARĪ³/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Shaw PH; Maughan TS; Clarke AR
Br J Cancer; 2011 Aug; 105(5):649-57. PubMed ID: 21811251
[TBL] [Abstract][Full Text] [Related]
10. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
Yan Y; Lu Y; Wang M; Vikis H; Yao R; Wang Y; Lubet RA; You M
Mol Cancer Res; 2006 Dec; 4(12):971-81. PubMed ID: 17189387
[TBL] [Abstract][Full Text] [Related]
11. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
[TBL] [Abstract][Full Text] [Related]
12. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
13. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.
Ohashi K; Takigawa N; Osawa M; Ichihara E; Takeda H; Kubo T; Hirano S; Yoshino T; Takata M; Tanimoto M; Kiura K
Cancer Res; 2009 Sep; 69(17):7088-95. PubMed ID: 19690148
[TBL] [Abstract][Full Text] [Related]
14. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.
Ninomiya T; Takigawa N; Ichihara E; Ochi N; Murakami T; Honda Y; Kubo T; Minami D; Kudo K; Tanimoto M; Kiura K
Mol Cancer Ther; 2013 May; 12(5):589-97. PubMed ID: 23443806
[TBL] [Abstract][Full Text] [Related]
15. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
16. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
18. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
19. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]